India Oncology Drugs Market Analysis Report 2022 to 2030

India Oncology Drugs Market Analysis

$ 3999

By 2030, it is anticipated that the India oncology drugs market will reach a value of $10.6 Bn from $3.6 Bn in 2022 and is expected to grow at a CAGR of 14.6% during 2022-30. The companies operating in the oncology drug in India market are Roche Diagnostics, Novartis Oncology and Celgene Corporation. This market is segmented on the basis of therapy modality and types of cancer. Factors such as increased awareness about cancer and its treatments, rising disposable incomes, and improved access to healthcare are some of the major drivers of growth in the Indian oncology drug market.

ID: IN10INPH018 CATEGORY: Pharmaceuticals GEOGRAPHY: India

Buy Now

India Oncology Drugs Market Analysis Summary

By 2030, it is anticipated that the India oncology drugs market will reach a value of $10.6 Bn from $3.6 Bn in 2022 and is expected to grow at a CAGR of 14.6% during 2022-30. India's oncology drug market is expanding quickly, which has led to a demand for more creative solutions. The incidence of cancer, the number of cancer patients, and the use of novel therapies are the main causes of this growth. With a projected 1.4 Mn new cases of cancer in the year 2020, the public health burden of cancer in India is steadily increasing. Due to issues with awareness, accessibility, and affordability, more than 80% of these patients present with advanced disease.

In India, between 60% and 75% of cancer patients receive treatment in private hospitals, where they run the risk of high OOP costs and distressed financing. India’s cancer burden is set to grow to over 1.5 Mn cases by 2025.

India Oncology Drugs Market Analysis

Market Dynamics

Market Growth Drivers Analysis

More people are able to access life-saving treatments and medications as a result of the rising prevalence of cancer and other related diseases, as well as the rising affordability of these drugs. Numerous foreign investors have been drawn to India's healthcare sector by the expansion of the oncology drug market. To help suffering patients afford medical care, the NPPA launched a Pilot on Trade Margin Rationalization for 42 anti-cancer drugs by using extraordinary powers in the public interest.

Following a decade of caution and organic growth, Indian pharmaceutical companies are currently on an acquisition binge. They appear to be primarily targeting anticancer medications. The country's Parliamentary panel has also demanded that middle-class households receive free cancer treatment through a government-funded health insurance program as patient numbers continue to rise. In response to increased research, India recently created Cervavac, its first locally produced vaccine, to prevent cervical cancer.

Market Restraints

Since most costs must be paid out-of-pocket, patients are burdened and may be constrained as a result.

Competitive Landscape

Key Players

Roche – Oncology Care (IND)
Novartis Oncology (IND)
Celgene (IND)
Johnson & Johnson – Janssen Pharma (IND)
Pharmacyclics (IND)
Healthkind Labs Pvt. Ltd. (IND)
Arlak Biotech (IND)
SwisscheM Healthcare Pvt. Ltd. (IND)

Notable Recent Deals

November 2022: The purchase of Viatris has been completed by Biocon Biologics, the biosimilars manufacturing division of Biocon. With full ownership of its collaboration assets, including the anti-cancer drug Bevacizumab, the anti-cancer drug Trastuzumab, the anti-cancer drug Pertuzumab, and the anticancer drug Pegfilgrastim, which is used to treat low white blood cells, the acquisition is expected to boost cancer therapy.

November 2021: Laurus Labs will invest in ImmunoACT, an IIT-Bombay-incubated company that is creating a domestic CAR T-cell therapy for treating particular types of blood cancers. On a fully diluted basis, the company purchased a 26.62% stake in ImmunoACT.

Healthcare Policies and Regulatory Landscape

The National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS) is being implemented under National Health Mission (NHM) for up-to-the-district level activities.

For the purpose of providing financial aid to cancer patients, the "Health Minister's Cancer Patient Fund (HMCPF)" within the Rashtriya Arogya Nidhi (RAN) has also been established. Additionally, the privately chosen insurance policy includes coverage for chemotherapy.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

India Oncology Drugs Market Segmentation

By Drug class

Cytotoxic drugs
- Alkylating agents
- Antimetabolites
- Others
Targeted drugs
- Monoclonal antibodies
- Others
Hormonal drugs
Others

By Therapy

Chemotherapy
Targeted therapy
Immunotherapy

By Indication

Lung cancer
Stomach cancer
Colorectal cancer
Breast cancer
Prostate cancer
Others

By Dosage form

Solid
- Tablets
- Capsules
Liquid
Injectable
- Prefilled syringes
- Others

By Distribution channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.